Economic burden of treatment failure in chronic lymphocytic leukemia patients

20187 citationsJournal Article

Authors

Song Wang · Janssen (United States)

Marie‐Hélène Lafeuille · Group for Research in Decision Analysis

Patrick Lefèbvre · Group for Research in Decision Analysis

Hela Romdhani · Group for Research in Decision Analysis

Bruno Émond · Group for Research in Decision Analysis

Mekré Senbetta · Janssen (United States)

Abstract

The cost of first-line TF is high and varies across first-line therapies. This should be considered when selecting the initial therapy in these patients.

Topics & Keywords

Chronic Lymphocytic Leukemia Research Chronic Myeloid Leukemia Treatments Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Current Medical Research and Opinion

Volume 34, Issue 6, pp. 1135-1142

DOI: 10.1080/03007995.2018.1464904

Field-Weighted Citation Impact: 0.44